Source
From GlobeNewswire
3 releases originally issued via GlobeNewswire. The issuing organizations are responsible for their content.
Aprea Therapeutics, Inc.
Aprea Therapeutics Announces Third Quarter 2026 Financial Results
Updated interim Phase 1 data for oral WEE1 inhibitor APR-1051 to be featured in an oral presentation at the 38th EORTC-NCI-AACR Symposium (ENA 2026)…
NRX Pharmaceuticals, Inc.
NRx Pharmaceuticals (Nasdaq:NRXP) Receives FDA Approval of Preservative-Free Ketamine Ahead of November 10 FDA Goal Date
October 30, 2026